Trifluoromethanesulfonic Acid

Trifluoromethanesulfonic Acid

SCHEMBL5258752

O=S(=O)(O)C(F)(F)F.O=c1ncc2ncccc2[nH]1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.43
ATAD2 Q6PL18 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 3/20 0.34
ALDH1A1 P00352 1/20 0.34
KHK P50053 1/20 0.34
RBP4 P02753 1/20 0.33
HRH4 Q9H3N8 1/20 0.33
ALOX12 P18054 1/20 0.33
HCAR2 Q8TDS4 1/20 0.32
PARP1 P09874 3/20 0.32
FGFR1 P11362 1/20 0.32
FLT1 P17948 1/20 0.32
KIF11 P52732 1/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
HSD17B10 Q99714 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167012 0.84 ATAD2 (0.56) DAOATAD2KDM4EALDH1A1HRH4
SCHEMBL2898417 0.83 ATAD2 (0.54) DAOATAD2KDM4EALDH1A1HRH4
Trifluoromethanesulfonic Acid SCHEMBL18692581 0.79 AXL (0.37) DAOATAD2L3MBTL1KDM4EALOX12
SCHEMBL27791126 0.75 ATAD2 (0.46) DAOATAD2KDM4EALDH1A1HRH4
Isoxazole SCHEMBL29144694 0.72 ATAD2 (0.44) DAOATAD2KDM4EALDH1A1HRH4
Quinoxaline SCHEMBL28065589 0.72 ALDH1A1 (0.37) L3MBTL1KDM4EALDH1A1ALOX12HPGD
Aminothiazole SCHEMBL29250377 0.71 ATAD2 (0.43) DAOATAD2KDM4EALDH1A1HRH4
Quinoline SCHEMBL5260404 0.70 ALDH1A1 (0.61) KDM4EALDH1A1ALOX12HSD17B10
Quinoline SCHEMBL28462227 0.69 ALDH1A1 (0.59) KDM4EALDH1A1ALOX12HSD17B10
Quinoline SCHEMBL28462226 0.69 ALDH1A1 (0.59) KDM4EALDH1A1ALOX12HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1594849-A4 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2007-07-04 EP disclosed
US-20070149500-A1 Compounds, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-28 US disclosed
EP-1594849-A2 COMPOUNDS, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2005-11-16 EP disclosed
WO-2004064741-A2 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC. (US) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149500-A1 Compounds, compositions, and methods ALPP, PCNA, MKI67 DAO 4340/4885ATAD2 3087/4885L3MBTL1 4571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.